LENZ TherapeuticsLENZ
About: LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
29% more capital invested
Capital invested by funds: $445M [Q3] → $573M (+$128M) [Q4]
19% more funds holding
Funds holding: 78 [Q3] → 93 (+15) [Q4]
4.08% more ownership
Funds ownership: 68.15% [Q3] → 72.23% (+4.08%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for LENZ.
Financial journalist opinion
Based on 3 articles about LENZ published over the past 30 days









